ARCHIVES

Long-Term Effect Of One Phase III Trial: Benefit For Thousands Of Patients

This article is from The Cancer Letter archive.

Vol. 32 No. 11 | November 27, 2009

Download PDF Visit The Full Archive

Related Articles

NIH Study Sections Use New Scoring Procedure

July 3, 1998

Competition Developing For Three New Regional Cooperative Group Awards; RFA Within Two Months

December 12, 1980

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

May 31, 2013

DeVita, Seffrin Present Cancer Czar PlanTo Feinstein, Without Committee Sign-Off

June 1, 2001

Selumetinib Displays Positive Results, 60% with Stable Disease

April 29, 2011

Bush Appoints Niederhuber Chairman of NCAB

August 2, 2002